ArticleBMC infectious diseases2026
Clinical phenotyping of polymyxin-associated nephrotoxicity and phenotype-specific prognostic utility of neutrophil-to-platelet ratio in carbapenem-resistant Acinetobacter baumannii infections.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant Acinetobacter baumannii (CRAB) infections remain therapeutically challenging, often necessitating last-line polymyxin therapy despite substantial nephrotoxicity. Conventional risk assessments for polymyxin-associated acute kidney injury (AKI) frequently overlook patient heterogeneity. We sought to delineate clinical phenotypes of polymyxin-associated AKI and determine whether the prognostic value of the neutrophil-to-platelet ratio (NPR) for mortality varies by phenotype.
methodsWe conducted a retrospective cohort study (2020–2025) of 547 patients with CRAB infections treated with polymyxins. Latent class analysis (LCA) identified clinical phenotypes using baseline risk factors and renal outcomes. Multivariable logistic regression incorporating restricted cubic splines (RCS), followed by piecewise regression, evaluated non-linear associations between NPR and 28-day mortality and tested effect modification by phenotype.
resultsLCA revealed three distinct phenotypes: Severe Renal Failure (Class 1, 15.2%), Low-risk/Stable (Class 2, 62.0%), and High-Comorbidity/Non-RRT Severe Injury (Class 3, 22.8%). Baseline characteristics and 28-day mortality varied significantly across these phenotypes (9.6% vs. 4.4% vs. 8.6%; p = 0.033). The prognostic value of NPR was exclusively significant in Class 2, where a critical threshold effect was identified at 0.0167 (breakpoint test p < 0.001). Below this threshold, mortality risk rose sharply—a non-linear relationship that was obscured in high-severity phenotypes (Class 1 and 3).
conclusionPatients with CRAB infections receiving polymyxins exhibit three distinct nephrotoxicity phenotypes. The prognostic utility of NPR is phenotype-specific, with a critical threshold at 0.0167 identifying relative immune insufficiency exclusively within the Low-risk/Stable subgroup. Clinical phenotyping is therefore a prerequisite for accurate biomarker interpretation and personalized risk stratification in this population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.